Asset Details
Do you wish to reserve the book?
Stage-Specific Immune Dysregulation in Multiple Sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Stage-Specific Immune Dysregulation in Multiple Sclerosis
Do you wish to request the book?
Stage-Specific Immune Dysregulation in Multiple Sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Stage-Specific Immune Dysregulation in Multiple Sclerosis
2014
Overview
A large body of data indicates that multiple sclerosis (MS) is an autoimmune disease which is initiated by CD4+ T-helper 1 (Th1) and Th17 cells that are reactive against proteins in the myelin sheath. MS typically begins with a relapsing-remitting course, punctuated by clinical exacerbations associated with the development of focal inflammatory lesions in central nervous system white matter, followed by a secondary progressive (SP) phase, characterized by a gradual accumulation of neurological disability associated with widespread microglial activation and axonal loss. The molecular and cellular basis for this transition is unclear, and the role of inflammation during the SP stage is a subject of active debate. As of now, no immunological biomarkers have been identified in MS that are predictive of the clinical course or therapeutic responsiveness to disease-modifying agents, or that correlate with new lesion development, cumulative lesion load, or degree of disability. The discovery of such biomarkers would greatly facilitate clinical management and provide power for smaller and shorter clinical trials. In this article, we discuss the literature on immunological biomarkers in MS with a focus on stage-specific differences and similarities.
Publisher
SAGE Publications,Mary Ann Liebert, Inc
Subject
/ Anti-Inflammatory Agents - therapeutic use
/ Biomarkers, Pharmacological - metabolism
/ Central Nervous System - drug effects
/ Central Nervous System - pathology
/ Encephalomyelitis, Autoimmune, Experimental - immunology
/ Encephalomyelitis, Autoimmune, Experimental - therapy
/ Humans
/ Multiple Sclerosis - immunology
/ Multiple Sclerosis - therapy
/ Reviews
